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Trends in Cost of Major Eye Diseases to
Medicare, 1991 to 2000
MARTIN SALM, MA, DANIEL BELSKY, BA, AND FRANK A. SLOAN, PHD
● PURPOSE: To estimate impacts of physician-diagnosed
eye diseases (age-related macular degeneration (AMD),
cataract, diabetic retinopathy, and glaucoma) on Medicare
payments in the periods 1991 to 1995 and 1996 to 2000.
● DESIGN: A retrospective cohort study to estimate pro-
gram payments per capita and in total for each of the
major eye diseases and the four eye diseases in total.
● METHODS: Data from the 1994 and 1999 National
Long-Term Care Survey (NLTCS) and medical claims to
Medicare from 1991 to 2000 were merged with the
NLTCS. Medicare payments for eye-related procedures on
persons with and without major eye diseases as reported on
Medicare claims and self-reported data from NLTCS.
● RESULTS: Overall, the burden of major eye diseases
was to increase Medicare spending by $4.8 billion (1999
USD) in 1991 to 1995 and by $4.5 billion in 1996 to
2000. The most expensive eye disease was cataract,
costing Medicare $3.8 billion in 1991 to 1995 and $3
billion in 1996 to 2000.
● CONCLUSIONS: Prevalence of major eye diseases in-
creased over time, but the effect of major eye diseases on
Medicare payments decreased, mainly as a result of lower
payments for cataract surgery in the later years. (Am J
Ophthalmol 2006;142:976–982. © 2006 by Elsevier
Inc. All rights reserved.)
E
YE DISEASE DISPROPORTIONATELY AFFECTS THE EL-
derly, who account for more than half of the persons
visiting ophthalmologists.1 The population is aging
rapidly, with the number of persons aged 65 expected to
more than double from 2000 levels by 2035.2 As the
population ages, overall spending on health care services is
expected to rise as a consequence.3–6 Increased spending
will almost inevitably lead to further pressures to reduce
private and public personal health care expenditures.
Vision care will be no exception. Accurate information on
the costs of eye diseases principally responsible for visual
impairment, age-related macular degeneration (AMD),
cataract, diabetic retinopathy (DR), and glaucoma, and
how such costs are changing over time will be important to
the decision-making process.
Previous studies of the cost of eye disease to Medicare
have focused on a single disease,7,8 and some have used
Medicare data from secondary sources.8,9 One study10 used
Medicare data more than 20 years old to evaluate the cost
of all ophthalmic surgery. There is more as well as more
recent information on the cost of eye care in other
countries;11–23 however, these studies rely on small samples
from few clinical settings or estimates of disease preva-
lence, sometimes combined with a projected or modeled
course of illness, to calculate costs, and they typically
examine only one disease. Clinical samples from only a
handful of hospitals present problems for generalization.
Studies of single diseases have excluded costs associated
with comorbid eye diseases. Most importantly, none of the
above studies documents trends in costs.
This study estimates the costs to Medicare of AMD,
cataract, DR, and glaucoma on the basis of a national
longitudinal sample of Medicare beneﬁciaries followed for
up to 10 years. It includes costs of common joint diagnoses.
Rather than summing procedure costs, we estimated costs
by calculating counterfactuals—costs incurred by Medi-
care beneﬁciaries who were identical on a number of
observable characteristics but were not diagnosed with a
major eye disease. In this way, we avoided attribution of
costs for procedures that would also have been used in
absence of the study diagnoses. The total annual cost of
the four eye diseases to Medicare in 1996 to 2000 was $6.7
billion (1999 USD), less than such annual costs for 1991
to 1995, which were $7.4 billion (1999 USD).
METHODS
THE SAMPLE CONSISTED OF MEDICARE BENEFICIARIES PAR-
ticipating in the 1994 and/or 1999 National Long-Term
Care Survey (NLTCS), a national household survey of the
US elderly, and Medicare claims and enrollment data,
merged with the NLTCS. This study was conducted with
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the NLTCS is a national random sample of Medicare
beneﬁciaries aged 65 years. In 1994, the NLTCS sample
consisted of 19,171 persons. For respondents in this sam-
ple, we used information on all years from 1991 to 1995 for
which Medicare payment data were available. The total
number of person-year observations for the 1991 to 1995
periods was 80,488. The 1999 NLTCS sample consisted of
19,079 persons which included both respondents inter-
viewed in 1994 who survived to the 1999 survey and were
added to the randomly selected sample from which the
1999 NLTCS sample was drawn, as well as about 5,000
sample persons who turned 65 between 1994 and 1999. For
the 1996 to 2000 sample, we used information on all years
between 1996 and 2000 for which Medicare payment data
were available. The total number of person-year observa-
tions for the 1996 to 2000 period was 74,477. Payment
data are not reported in Medicare claims for beneﬁciaries
enrolled in Medicare risk plans. Persons enrolled in a
Medicare risk plan for more than six months in a year were
excluded from our analysis. Medicare enrollment ﬁles
provided data on demographic information, dates of ﬁrst
diagnosis of AMD, cataract, DR, and glaucoma, and
Medicare payments made on behalf of sample persons. The
NLTCS provided information on nursing home residence
status, race, and years of education.
Diagnosis of AMD, cataract, DR, and glaucoma were
provider coded and identiﬁed from ICD-9-CM diagnosis
codes (codes listed in Supplementary Appendix A avail-
able at AJO.com). By using Medicare claims ﬁles from Part
B and outpatient physician visits, we estimated annual
Medicare payments related to AMD, cataract, DR, and
glaucoma for each person in each year, on the basis of
CPT24–29 or ICD-930–32 procedure codes in vision care (see
Supplementary Appendices B and C available at AJO.
com). All payments were converted to constant 1999 US
dollars by multiplying nominal payments with the Con-
sumer Price Index in 1999, and dividing by the Consumer
Price Index for the current year.
We imputed values for missing data on years of educa-
tion and race by using a sequence of regression models.33
Imputations were obtained by means of imputation and
variance estimation software.34
We used linear regression to estimate the effects of the
four major eye diseases on Medicare payments. We esti-
mated separate regression models (Stata 8.0, StataCorp,
College Station, Texas, USA) for the 1991 to 1995 periods
and 1996 to 2000 periods. The dependent variable was
Medicare payment for a beneﬁciary per year for vision care
related to the four diseases.
For the cost analysis for each disease, we included a set
of independent variables; separate variables indicated
whether the observation was in the year of ﬁrst diagnosis,
the year after ﬁrst diagnosis, years 3 and 4 of diagnosis, or
year 5 after diagnosis. The count of number of years after
ﬁrst diagnosis started in the year of ﬁrst diagnosis (year 1).
Once a sample person was diagnosed with an eye disease,
the person was assumed to have the disease for the rest of
the observational period or for life. We also controlled for
the effects of joint diagnoses of the most common types:
cataract and glaucoma, and cataract and AMD. Persons
with a joint diagnosis had a diagnosis of both conditions at
some time in the past, not necessarily at the same date.
The date of a joint diagnosis was deﬁned as the time of the
ﬁrst diagnosis for either disease. Medicare claims data did
not report information on diagnosis before 1991; thus,
patients with a ﬁrst diagnosis before 1991 could only be
identiﬁed as having ﬁrst been diagnosed in 1991. We
included an independent identifying variable for persons
ﬁrst diagnosed in 1991 for each disease.
We also controlled for age, gender (male), race (white vs
nonwhite), years of education, and the Diagnostic Cost
Group (DxCG, Inc, Boston, Massachusetts, USA) score
computed from the diagnoses and procedures the beneﬁciary
had in the previous year, except for the eye diseases.34 The
DxCG score is a comprehensive measure of overall health,
which is predictive of future health care spending on behalf of
an individual. The DxCG score was calculated for each
person for every year from 1991 to 2000 and was based on
diagnosis and procedure codes recorded on sample persons’
Medicare claims in the previous year (DxCG risk adjustment
software, analytic guide release 6.0). In addition, we con-
trolled for nursing home residency and the number of months
in the current year a person was enrolled in a Medicare risk
plan. In our estimation procedure, observations were
weighted to reﬂect the elderly Medicare population in 1994
and 1999, respectively. We estimated robust standard errors
that allow for a possible correlation in Medicare payments for
the same person in different years.
We used a counterfactual approach to calculate Medi-
care payments attributable to AMD. A counterfactual
approach aims to compare payments on behalf of sample
persons, who except for not having a diagnosis of AMD,
for example, are identical to AMD patients. These persons
could be called “AMD patients without an AMD diagno-
sis.” Once we calculated the costs for an “AMD patient
without AMD,” we calculate the costs attributable to
AMD as the difference in cost for the actual AMD patient
and the “AMD patient without AMD”. This counterfac-
tual design differs from previous approaches that simply
calculate cost for procedures used on behalf of AMD
patients without employing a control group of otherwise
identical patients. Calculating total costs incurred by
AMD patients includes costs patients might have incurred
in the absence of the diagnosis, for example for the care of
comorbidities not related to AMD or for routine eye
exams. Without controlling for the costs AMD patients
would have incurred had they not suffered from the
disease, previous estimates inadvertently attribute costs to
AMD that are more properly attributed to other reasons.
We used the same approach to calculate mean annual
payments per Medicare beneﬁciary attributable to the three
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computed the burden of eye diseases separately for 1991 to
1995 and 1996 to 2000. In our calculations, observations were
weighted to reﬂect the elderly Medicare population in 1994
and 1999, respectively. To calculate total program payments
attributable to each of the four eye diseases and to all four
diseases combined, we multiplied per beneﬁciary payments by
the number of aged Medicare beneﬁciaries in the year of the
NLTCS survey (1994 and 1999).
We used a sample of 200 bootstrap runs to calculate
standard errors of mean payments.
RESULTS
MEAN ANNUAL PAYMENT PER MEDICARE BENEFICIARY FOR
vision care (in 1999 USD) was $236 during 1991 to 1995 and
$202 during 1996 to 2000 (Table 1). The eye diseases
examined in this study were quite common. In the 1991 to
1995 period, 3.4% of sample persons had a Medicare claim
containing a diagnosis of AMD in the current year, 23.8%
with cataract, 0.8% with DR, and 6.9% with glaucoma. A
total of 1.1% of sample persons had a diagnosis of both
cataract and AMD, and 2.3% had both cataract and glau-
coma. In 1996 to 2000, diagnosis rates were higher for all
diseases; the share of persons with a diagnosis of eye disease in
the current year was 4.5% for AMD, 26.2% for cataract, 1.3%
for DR, 8.5% for glaucoma, 2.6% for a joint diagnosis of
cataract and glaucoma, and 1.3% for a joint diagnosis of
glaucoma and AMD. In 1991 to 1995, the mean age in the
sample was 73.8 years; 42.5% of sample beneﬁciaries were
men; 85.5% were white; and 4.5% were nursing home
residents. On average, the beneﬁciaries had 11.1 years of
education. In 1996 to 2000, mean age was 74.4 years; 88.9%
were white; and nursing home residency decreased to 4.0%.
Although there are some differences in the parameter
estimates, patterns in key variables are similar between
1991 to 1995 and 1996 to 2000 (Table 2). A diagnosis of
AMD increased Medicare payments (1999 USD) in the
year of ﬁrst diagnosis by $425 in 1991 to 1995 and $579 in
1996 to 2000. The rise in Medicare payments in subse-
quent years was lower. A diagnosis of cataract increased
Medicare payments in the year of diagnosis by $680 in
1991 to 1995 and by $466 in 1996 to 2000. The effect of
a cataract diagnosis on Medicare payments were lower in
subsequent years, but in years 5 of the diagnosis, pay-
ments were still $194 in 1991 to 1995 and $204 in 1996 to
2000. Among the four eye diseases, those with a diagnosis
of DR had the highest spending per diagnosed person.
Medicare payments in the year of diagnosis were increased
by $1,630 in 1991 to 1995 and $1,176 in 1996 to 2000.
The effect on payments in subsequent years decreased to
$333 in 1991 to 1995 ($366 in 1996 to 2000) in years 5
of the diagnosis. A diagnosis of glaucoma increased of
Medicare payments by $306 in 1991 to 1995, and $287 in
1996 to 2000 in the year of ﬁrst diagnosis and by $196 in
1991 to 1995 and $37 in 1996 to 2000 in year 5 of the
diagnosis.
There were important interaction effects of Medicare
payments for both glaucoma and AMD with cataract.
Payments were increased by $893 in 1991 to 1995 ($1,290
in 1996 to 2000) in the ﬁrst year of a joint diagnosis of
TABLE 1. Characteristics of Medicare Beneﬁciaries Participating in 1994 and/or 1999 National Long-Term Care Survey
Characteristic
1991 to 1995 Period 1996 to 2000 Period
Mean* SD Mean* SD
Medicare payment for vision care
† (in 1999 USD) 236.37 1327.6 201.66 963.70
Fraction of claims in year with recorded diagnosis of
AMD 0.034 0.209 0.045 0.238
Cataract 0.238 0.453 0.262 0.460
Diabetic retinopathy 0.008 0.096 0.013 0.115
Glaucoma 0.069 0.280 0.085 0.304
Cataract and AMD 0.011 0.123 0.013 0.136
Cataract and glaucoma 0.023 0.171 0.026 0.175
Age 73.835 7.674 74.410 8.141
Male gender 0.425 0.484 0.426 0.485
White 0.855 0.318 0.889 0.290
Years of education 11.157 3.656 11.163 3.674
DxCG score 0.719 0.885 0.841 1.063
Nursing home resident 0.045 0.266 0.040 0.240
Months enrolled in risk plan 0.048 0.003 0.102 0.004
Observations 80,488 74,477
AMD  age-related macular degeneration; DxCG  diagnostic cost group; SD  standard deviation; USD  United States dollars.
*Sample means account for population weights.
†Payment on behalf of procedure and device codes listed in Appendices B and C (available at AJO.com).
AMERICAN JOURNAL OF OPHTHALMOLOGY 978 DECEMBER 2006cataract and AMD, and by $1,133 in 1991 to 1995 and
$1,294 in 1996 to 2000 in the ﬁrst year of a joint diagnosis
of cataract and glaucoma.
After controlling for diagnoses of diseases, such demo-
graphic factors as age and gender only had a small effect on
Medicare payments, and there was no statistically signiﬁ-
cant effect for race. Patients with comorbidities, as mea-
sured by the DxCG score, received more vision care,
whereas nursing home residents received less of such care.
Being a resident of a nursing home decreased payments by
$114 per year in 1991 to 1995 for all major eye diseases
($150 per year in 1996 to 2000). Mean payments per
TABLE 2. Medicare Payments per Beneﬁciary per Year for Vision Care: Regression Results
†
Characteristic Payment Amount (USD) 1991 to 1995 Payment Amount (USD) 1996 to 2000
AMD
In year of ﬁrst diagnosis 424.69** (53.77) 578.74** (70.51)
In year 2 5.61 (50.81) 80.18 (61.78)
In years 3 and 4 77.33 (55.84) 100.70 (62.46)
In years 5 59.13 (91.92) 103.62* (60.61)
Cataract
In year of ﬁrst diagnosis 680.20** (27.36) 465.51** (28.51)
In year 2 328.51** (21.27) 201.92** (20.51)
In years 3 and 4 235.43** (19.17) 201.10** (13.17)
In years 5 194.41** (38.60) 204.19** (13.21)
Diabetic retinopathy
In year of ﬁrst diagnosis 1,629.88** (265.80) 1,175.53** (206.34)
In year 2 507.28** (130.82) 472.42** (98.25)
In years 3 and 4 344.23** (132.65) 573.26** (113.33)
In years 5 333.31 (273.34) 365.52** (111.91)
Glaucoma
In year of ﬁrst diagnosis 306.39** (52.85) 286.66** (47.17)
In year 2 130.08** (46.20) 105.81** (46.29)
In years 3 and 4 88.83 (50.98) 136.28** (35.27)
In years 5 196.08** (86.02) 36.76 (33.98)
Cataract and AMD

In year of ﬁrst diagnosis 892.74** (249.42) 1,289.82** (311.28)
In year 2 227.16* (119.44) 587.12* (335.35)
In years 3 and 4 73.65 (70.11) 105.64 (81.97)
In years 5 5.25 (69.47) 22.46 (54.12)
Cataract and glaucoma
‡
In year of ﬁrst diagnosis 1132.50** (200.13) 1,293.94** (402.63)
In year 2 454.82** (113.83) 479.84* (229.29)
In years 3 and 4 260.01** (65.81) 137.85* (65.22)
In years 5 26.15 (60.89) 102.89** (33.27)
Age 2.48** (0.76) 0.30 (0.53)
Male gender 20.46* (9.18) 13.14 (5.44)
White 20.23 (13.51) 1.12 (9.68)
Years of education 0.90 (1.36) 1.05 (0.66)
DxCG score 19.89** (6.97) 15.28* (5.08)
Nursing home resident 114.35** (18.60) 149.50** (10.84)




AMD  age-related macular degeneration; DxCG  diagnostic cost group.
*Signiﬁcant at 5%.
**Signiﬁcant at 1%.
†Regression accounts for population weights. Standard errors account for clustering at the
respondent level. Standard deviations of estimation coefﬁcients are in parentheses. Coefﬁcients for
binary variables whether ﬁrst diagnosis of diabetic retinopathy, glaucoma, cataract, and AMD was in
1991 are not shown.
‡Year of diagnosis is based on the earlier diagnosis.
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from $227 in 1991 to 1995 to $197 in 1996 to 2000 (Table
3). Total annual Medicare payments for all four eye
diseases were $7.4 billion in 1991 to 1995 and $6.7 billion
in 1996 to 2000, with the largest reduction in payments
being for cataract; annual Medicare payments attributable
to cataract declined from $6.1 billion in 1991 to 1995 to
$4.8 billion per year in 1996 to 2000. Annual payments
attributable to glaucoma were $1.3 billion in 1991 to 1995
and $1.2 billion in 1996 to 2000. Such payments for AMD
and DR were substantially lower than this.
Future Medicare payments for vision care depend on two
components: (1) the future mean per-beneﬁciary payment for
vision care, and (2) the number of Medicare beneﬁciaries.
The aged Medicare population is predicted to grow to 38.2
million in 2010 and 43.8 million in 2015.2 The future
trajectory of per-beneﬁciary Medicare payments for vision
care is unknown. However, if the trend of declining per-
beneﬁciary payments were to continue (linearly) into the
future, total annual Medicare payments for vision care would
decline to $5.0 billion in 2010 and to $4.4 billion in 2015 (in
1999 USD).
DISCUSSION
TOTAL MEDICARE PAYMENTS FOR VISION-RELATED CARE ON
behalf of persons with the four major eye diseases amounted
to from $6.5 to $7.5 billion (1999 USD) annually during the
1990s, or about 4% of total Medicare payments overall. In
spite of the growth of the age 65 population during the
1990s, a trend which is expected to continue throughout the
21st century, four total Medicare payments in 1999 US
dollars actually were lower in the second half than in the ﬁrst
half of the 1990s. This largely reﬂects reductions in Medicare
reimbursement rates for cataract care.35,36 Institution of the
Resource-Based Relative Value Scale (RBRVS) let to a
substantial drop in reimbursement rates. Reimbursement for
the most commonly coded cataract surgery declined through-
out the decade from $1,092 (1999 USD) in 1991 to $536
(1999 USD) by 2000.
By contrast, payment for care of beneﬁciaries with AMD
increased during the period. Photodynamic and anti–
vascular endothelial growth factor therapies, the principal
treatments for AMD, were introduced after the period our
study examines. The increase in costs we documented may
reﬂect higher utilization of general eye care services by
beneﬁciaries with AMD as well as an increase in rates of
thermal laser treatment. After the introduction of new
technologies and drugs treating AMD, such payments may
be expected to increase further.
Medicare payments attributable to DR rose over the
1990s. There are several possible explanations for this
trend. Attention to ophthalmologic evaluation and
screening of diabetics increased over the study period.37–39
In addition, introduction in the later 1990s of coding for
indocyanine green angiography as a diagnostic27 and laser
photocoagulation as a treatment28 likely contributed to
increasing payments. Payments for glaucoma were stable
over time. But importantly, until 2006, Medicare did not
cover the cost of prescription drugs, which are particularly
important for treatment of glaucoma.
Our study differs from previous research on this topic in
four major respects. First, patients were followed for several
years in our study. For all four diseases, there were substantial
reductions in Medicare payments as time since initial diag-
nosis increased. For some diseases, in particular AMD, this
pattern plausibly reﬂects limits in effective therapies, whereas
for others, such as cataract, lower payments probably reﬂect
the existence of effective therapy. Second, rather than con-
ﬁne the analysis to a single disease, our analysis incorporated
all four major eye diseases affecting the elderly population. For
the more prevalent diseases, our analysis allowed for cost
effects when two diseases coexist. Joint diagnoses resulted in
TABLE 3. Medicare Payments for Vision Care: Burden of Illness Estimates
Payments Attributable To:*
Payments per Medicare Beneﬁciary†
(in 1999 USD) Total Program Payments‡ (in Millions of 1999 USD)
1991 to 1995 1996 to 2000 1991 to 1995 1996 to 2000
AMD 15.98 (2.47) 21.61 (2.18) 524.12 (81.07) 733.25 (74.21)
Cataract 187.25 (6.21) 140.04 (5.45) 6,141.61 (203.75) 4,751.70 (184.956)
Diabetic retinopathy 11.51 (1.86) 17.38 (1.62) 377.52 (61.17) 589.72 (55.24)
Glaucoma 38.26 (4.18) 36.31 (2.57) 1,254.89 (137.36) 1,232.04 (87.34)
All four diseases 226.65 (7.97) 196.65 (7.47) 7,432.24 (261.44) 6,672.53 (253.734)
AMD  age-related macular degeneration; USD  United States dollars.
*Standard errors are in parentheses.
†Difference between mean predicted payments with actual prevalence of disease and counterfactual mean predicted payments with zero
prevalence of disease.
‡Calculated as payments attributable to disease per Medicare beneﬁciary times the number of aged Medicare beneﬁciaries in 1994 and
1999, respectively.
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common not to have a control group. By contrast, our results
controlled for what cost would have been absent the diagnosis
for the eye disease. Our estimates reﬂected the difference in
costs between persons with and without the diagnosis after
controlling for all other characteristics. Fourth, the sample
sizes were both national and larger than those used in
previous studies.
Our estimates of costs to Medicare for care of cataract are
somewhat higher than the $4 billion (1999 USD) reported in
a previous study,41 even when one accounts for the differ-
ences in study years. The difference may be attributable to
differences in the methodologies of the two studies. We
measured costs to Medicare from the date of ﬁrst diagnosis. By
contrast, the $4 billion estimate in the other study included
ophthalmologic services obtained within a time window
starting from 90 days before surgery to four years after surgery.
Our estimates included a period of watchful waiting as well as
the time around surgery and, for some sample persons, a
period of time extending several years after surgery.
One previous study, examining costs of primary open-angle
and exfoliation glaucomas, a narrower deﬁnition than the one
used in our study, at 12 hospitals in the United States and
Sweden estimated two-year costs at $2,371 and $2,428 in 1994
(1999 USD) in the United States and Sweden, respectively.15
Studies in other countries found mean annual costs for
glaucoma patients of $280 to $423 (Canada, 2001),14 $594
(The Netherlands, 1996),21 $447 (France, 1991 to 1994),15
and $705 (United Kingdom, 1991 to 1994).15 Examining all
patients with diagnoses of glaucoma, as we did, unsurprisingly
yields lower average estimates of charges than do studies of
hospital populations,16,21 or including only patients with
extensive follow-up.14 In the case of the results from France
and the United Kingdom, the study sites might have tended
to include service providers treating more severe glaucomas
given the study’s focus on examining the cost of new drug
therapies. Further, none of these studies used a counterfactual
design, raising the possibility that some of the treatment costs
included were for procedures unrelated to glaucoma.
A previous study of the costs associated with severe DR
resulting in blindness estimated the per person annual cost
to Medicare and Medicaid in 1990 at $49,899 (costs are
derived from previously published estimates43). In addition
to focusing on the most expensive cases of the disease, the
authors also included drug costs, which were excluded in
our study.
We acknowledge several limitations in our study. First,
our analysis only included costs of care incurred by
Medicare. Most importantly, we did not include prescrip-
tion drug expense, which, during the observational period,
was excluded from Medicare coverage. Second, we did not
include such intangible costs as those associated with low
vision or blindness. Although such outcomes are fortu-
nately uncommon, they are costly to patients and their
families when they do occur. More frequent are losses in
functional status attributable to impaired vision in elderly
populations.44 Third, observed changes in disease preva-
lence and treatment utilization may reﬂect changes in
coding practices. Particular diagnoses or treatments may
have become more or less common over the study period as
a result of issues unrelated to disease prevalence or severity,
such as improved diagnostic testing, increased coding as a
result of audit pressures, or the introduction of new billing
or claims software. Fourth, technological change is a
dynamic process, as is third-party payment policy. The
experience of the 1990s may not be repeated in future years.
Phasing in of the RBRVS greatly altered Medicare reim-
bursement for certain treatments. In particular, the cost
trends for cataract may not be repeated for technologies
developed to treat the other eye diseases, many of which
were introduced well after the RBRVS. Finally, our coun-
terfactual design does not ensure that our control group is
a perfect match. Our estimation is valid only under the
assumption that we could control for all important deter-
minants of payments.40–42
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Diagnosis Codes Used to Identify Major Eye Diseases






Suspected 365.0, 365.00, 365.01, 365.04
Primary open angle 365.1, 365.10, 365.11, 365.12, 365.15
Narrow angle 364.73, 365.02, 365.2x, 365.61
Other 365.03, 365.13, 365.14, 365.24, 365.3x, 365.4x, 365.5x, 365.6, 365.60, 365.62, 365.63,
365.64, 365.65, 365.8x, 365.9
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Procedure Codes Used to Identify Major Eye Diseases
Disease CPT or ICD-9 Procedure Codes
For all diseases 90000–90650
††, 99201–99499*, (where accompanied by provider specialty code 18 or 41,
costs obtained from Part B records only)
92002, 92012, 92019, 92004, 92014, 92018, 92225, 92226, 92235, 92250, 92392
95.02, 95.03, 95.04, 95.05, 95.06, 16.21, 95.12, 95.11, 95.13, 95.16, 95.31, 95.32, 95.33,
95.36
Diabetic retinopathy
With any ocular complication 92260, 76511, 76512, 76513, 67208, 67210, 67220***, 67227, 67228
With any form of diabetic retinopathy 92287, 92235, 92240**, 92287
14.11, 14.19, 14.21–14.27, 14.29, 14.31–14.35, 14.39
Claims only with 362.02 as primary
diagnosis
67036, 67038, 67039, 67040, 67108, 67109, 67112
14.72, 14.74, 14.79, 15.51-14.55, 15.59, 14.9, 14.41, 14.49
Glaucoma
Any form 65820, 92135**, 92020, 92081–92083, 92100, 92120, 92130, 92140, 65850, 65855, 66150,
66155, 66160, 66165, 66170, 66172








95.05, 95.21, 95.26, 12.11, 12.14, 12.22, 12.34, 12.35, 12.39, 12.54, 12.55, 12.61–12.65,
12.69, 12.71–12.73, 12.93
Narrow angle only 65865, 65870, 65880, 66500, 66505, 66600, 66625, 66830, 66761, 66762
Other 92287, 65900, 65930
Cataract 66830, 66840, 66850, 66852, 66920, 66930, 66940, 66983, 66984, 66985, 66986, 76516,
76519
13.1, 13.11, 13.19, 13.2, 13.3, 13.4, 13.41–13.43, 13.5, 13.51, 13.59, 13.6, 13.64–13.66,
13.69, 13.7, 13.70–13.72, 13.8
Age-related macular degeneration
Any form 92235, 92240, 92283, 92284, 92287, 67208, 67210, 67218
95.07, 14.21–14.25, 14.27, 14.29, 14.72, 14.74, 14.79
Wet only (362.52, 362.53) 67220**
*Codes ﬁrst used in 1992.
**Codes ﬁrst used in 1997.
***Codes ﬁrst used in 1999.
†Codes dropped between 1992 and 1994.
††Codes dropped in 1993.
‡Codes ﬁrst used between 1992 and 1994
Codes dropped before 1991 or added and dropped between 1992 and 1994.
Codes included only where associated with provider specialty codes 18 (ophthalmology) or 41 (optometry). Costs for these codes are
included only from Medicare Part B.
APPENDIX C.
Device Codes Used to Identify Major Eye Diseases
Disease HCPCS Device Codes
All diseases (eyeglass lenses and frames,
contact lenses, and low vision aids)
V2020, V2025, V2100–V2499, V2610, V2618, V2730, V2755, V2770, V2780, S0500,
S0512, S0513, S0514, V2500–V2599, V2600, V2610, V2615
Glaucoma (aqueous shunt) L8612
Cataract (intraocular lenses) V2630, V2631, V2632, Q1001, Q1002, Q1003, Q1004, Q1005
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